BioXcel Therapeutics (BTAI) EBIT Margin Growth (1y) (2023 - 2026)
Powered by 
Analysis
BioXcel Therapeutics (BTAI) EBIT Margin Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | -1.23 Mn |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | 760,945.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 760,945.00 |
| Mar 31, 2026 | 104,869.00 |
| Dec 31, 2025 | -114,947.00 |
| Sep 30, 2025 | -737,211.00 |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | -185,959.00 |
| Dec 31, 2024 | 241,896.00 |
| Sep 30, 2024 | 701,708.00 |
| Jun 30, 2024 | 990,248.00 |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 1.43 Mn |